Literature DB >> 29856548

Antipsychotic drugs: challenges and future directions.

Oliver H Howes1,2,3, Stephen J Kaar1.   

Abstract

Entities:  

Year:  2018        PMID： 29856548      PMCID： PMC5980606          DOI： 10.1002/wps.20522

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  11 in total

Review 1.  Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia.

Authors:  Michael F Green
Journal:  J Clin Psychiatry       Date:  2016-02       Impact factor: 4.384

Review 2.  Secondary negative symptoms - A review of mechanisms, assessment and treatment.

Authors:  Matthias Kirschner; André Aleman; Stefan Kaiser
Journal:  Schizophr Res       Date:  2016-05-24       Impact factor: 4.939

3.  Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.

Authors:  J Lally; O Ajnakina; M Di Forti; A Trotta; A Demjaha; A Kolliakou; V Mondelli; T Reis Marques; C Pariante; P Dazzan; S S Shergil; O D Howes; A S David; J H MacCabe; F Gaughran; R M Murray
Journal:  Psychol Med       Date:  2016-09-08       Impact factor: 7.723

Review 4.  Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses.

Authors:  Stefan Leucht; Sandra Hierl; Werner Kissling; Markus Dold; John M Davis
Journal:  Br J Psychiatry       Date:  2012-02       Impact factor: 9.319

Review 5.  Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.

Authors:  Stefan Leucht; Claudia Leucht; Maximilian Huhn; Anna Chaimani; Dimitris Mavridis; Bartosz Helfer; Myrto Samara; Matteo Rabaioli; Susanne Bächer; Andrea Cipriani; John R Geddes; Georgia Salanti; John M Davis
Journal:  Am J Psychiatry       Date:  2017-05-25       Impact factor: 18.112

6.  Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.

Authors:  Arsime Demjaha; Robin M Murray; Philip K McGuire; Shitij Kapur; Oliver D Howes
Journal:  Am J Psychiatry       Date:  2012-11       Impact factor: 18.112

Review 7.  Schizophrenia: an integrated sociodevelopmental-cognitive model.

Authors:  Oliver D Howes; Robin M Murray
Journal:  Lancet       Date:  2013-12-06       Impact factor: 79.321

Review 8.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

9.  Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia.

Authors:  Andrew J Pocklington; Elliott Rees; James T R Walters; Jun Han; David H Kavanagh; Kimberly D Chambert; Peter Holmans; Jennifer L Moran; Steven A McCarroll; George Kirov; Michael C O'Donovan; Michael J Owen
Journal:  Neuron       Date:  2015-06-03       Impact factor: 17.173

10.  Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.

Authors:  Stefan P Brugger; Oliver D Howes
Journal:  JAMA Psychiatry       Date:  2017-11-01       Impact factor: 21.596
View more
  8 in total

Review 1.  Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Authors:  Robert C Smith; Stefan Leucht; John M Davis
Journal:  Psychopharmacology (Berl)       Date:  2018-11-30       Impact factor: 4.530

Review 2.  Opportunities in precision psychiatry using PET neuroimaging in psychosis.

Authors:  Jennifer M Coughlin; Andrew G Horti; Martin G Pomper
Journal:  Neurobiol Dis       Date:  2019-03-20       Impact factor: 5.996

Review 3.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

4.  The effect of NMDA-R antagonist, MK-801, on neuronal mismatch along the rat auditory thalamocortical pathway.

Authors:  Gloria G Parras; Catalina Valdés-Baizabal; Lauren Harms; Patricia T Michie; Manuel S Malmierca
Journal:  Sci Rep       Date:  2020-07-24       Impact factor: 4.379

Review 5.  Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges.

Authors:  Oriane Razakarivony; Adrian Newman-Tancredi; Luc Zimmer
Journal:  Transl Psychiatry       Date:  2021-01-07       Impact factor: 6.222

Review 6.  Advances and Challenges in Intranasal Delivery of Antipsychotic Agents Targeting the Central Nervous System.

Authors:  Manisha Pandey; Neha Jain; Jovita Kanoujia; Zahid Hussain; Bapi Gorain
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

7.  The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia.

Authors:  Stephen J Kaar; Ilinca Angelescu; Matthew M Nour; Tiago Reis Marques; Alice Sharman; Anil Sajjala; John Hutchison; Philip McGuire; Charles Large; Oliver D Howes
Journal:  Psychopharmacology (Berl)       Date:  2022-09-12       Impact factor: 4.415

Review 8.  Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.

Authors:  Susan F Sonnenschein; A Grace
Journal:  Expert Opin Ther Targets       Date:  2020-11-26       Impact factor: 6.902
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.